Icahn School of Medicine at Mount Sinai


 

Developing KCNQ Channel Openers as Novel Antidepressants: Rationale for Targeting the KCNQ2/3 Channels for Depression & Anhedonia

10 views
May 18, 2021
0 Comments
Login to view comments. Click here to Login
The Friedman Brain Institute